

## PharmTox Fights COVID-19 Week of January 4-8, 2021

# 2021

### Accepted Review by Basnakian Team



Research associates Christopher Moore, PhD, MBA, and Alena Savenka, MS, and professor Alexei Basnakian had a review article accepted to the International Journal of Molecular Sciences: Molecular Toxicology. The review is titled “TUNEL Assay: A Powerful Tool for Kidney Injury Evaluation”. It critically analyzes 145 papers published in recent years that used the TUNEL assay. In the review, the authors also introduce a novel classification of TUNEL assay patterns, which will help pathologists to determine mechanisms of cell death. The review establishes the department’s DNA Damage and Toxicology Core led by Dr. Basnakian as one of the world leaders in this assay.

### Welcome to Li Jiang



Welcome to research technician Li Jiang. Li joined assistant professor Nirmala Parajuli’s laboratory in December. Li received her undergraduate degree in chemistry and mathematics from Philander Smith College in 2016, where she had a full scholarship. She also completed some graduate studies in psychology and mental health counseling at Harding University and a biochemistry course from Harvard. Li worked as a volunteer at Arkansas Children’s Hospital in the Radiology Department, during which time she published a paper. Li is very grateful to be a part of the department, stating “Thank you so much for every opportunity UAMS is offering and I hope to be able to work with more colleagues here and gain the valuable experience I need before my next journey.”

### Dr. Zheng Attends Virtual NINDS Conference

Associate professor Fang Zheng attended the NINDS “Curing the Epilepsies 2021: Setting Research Priorities” conference. The virtual conference, held January 4-6, was organized by NINDS to identify knowledge gaps and transformative ideas to cure epilepsy. The Transformative Research Priorities for the Epilepsies were identified by the AES Epilepsy Research Benchmark Stewards Committee based on input from an NINDS Request for Information from the research community and patient advocates in the Epilepsy Leadership Council as part of their process to update the Epilepsy Research Benchmarks.

